The Abdala vaccine candidate developed by Cuba against the coronavirus, the first created in Latin America, displays an efficacy of 92.28% against the disease, the laboratory which developed it announced on Monday (June 21).
Read also: These eight preconceived ideas circulating about anti-Covid vaccines
"Abdala, CIGB vaccine candidate from Cuba, shows 92.28% efficacy after three doses,"
announced on Twitter the Center for Genetic and Biotechnological Engineering (CIGB), while Abdala, in the final phase of clinical trials, must receive official authorization from the Cuban authorities in late June or early July.